Supernus Pharma (SUPN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
March 12, 2015 7:21 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.
Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More
